Biosimilars taking a toll on AbbVie, but sales still beat forecasts

26 July 2019

US biopharma major AbbVie (NYSE: ABBV) today posted second-quarter 2019 financial results, showing that net revenue fell 0.3% to $8.26 billion, but still beat the average analyst estimate of $8.10 billion. Adjusted net revenues were flat on a reported basis and increased 1.5% operationally. AbbVie’s shares were up 2% pre-market.

Second-quarter diluted earnings per share (EPS) of $0.49 on a generally accepted accounting principle (GAAP) basis, versus $1.26 in the like 2018 quarter. Adjusted diluted EPS of $2.26 compared with $2.00. Net earnings were $741 million, compared with $1.98 in the like 2018 period, as AbbVie recorded a $2.28 billion charge related to future payments associated with plaque psoriasis drug Skyrizi (risankizumab), which is partnered with Boehringer Ingelheim.

For 2019, the company raised it adjusted earnings per share forecast to between $8.82 and $8.92 from a prior range of $8.73 to $8.83.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK